Vir Biotechnology Inc. filed SEC Form 8-K: Regulation FD Disclosure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2025

Vir Biotechnology, Inc.

(Exact name of Registrant as Specified in Its Charter)

Registrant’s Telephone Number, Including Area Code: (415) 906-4324

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As previously announced, Vir Biotechnology, Inc. (the “Company”) is holding a virtual investor event at 5:00 a.m. PT / 8:00 a.m. ET on January 8, 2025, to discuss initial data from Phase 1 clinical studies evaluating its dual masked T-cell engagers: VIR-5818, targeting a variety of HER2-expressing solid tumors, and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (the “Data”). A live webcast of the virtual investor event will be made available on https://investors.vir.bio and will be archived there for 30 days.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Press Release

On January 8, 2025, the Company issued a press release announcing the Data. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Consent of Ernst & Young LLP

On February 26, 2024, the Company filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Form 10-K”). The consent of Ernst & Young LLP (“Ernst & Young”), the Company’s independent registered public accounting firm, filed as Exhibit 23.1 to the 2023 Form 10-K (the “Consent”), inadvertently omitted the electronic signature of Ernst & Young. To correct this inadvertent clerical error, a copy of the Consent with the conformed signature is filed herewith as Exhibit 23.1 and is incorporated herein by reference.

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.